Min Bao
Chief Medical Officer Kali Therapeutics
Dr. Min Bao is the Chief Medical Officer at Kali Therapeutics from the US. Min brings 25+ years of industry experience across multiple therapeutic areas from pre-IND and phase 1-4 studies. During her 22-year tenure at Genentech/Roche with increasing responsibilities including the role of Global Development Lead, her significant contributions and clinical leadership resulted in global approvals in multiple autoimmune diseases and severe COVID-19. Prior to Kali, she took SVP roles at AnaptysBio and Alpine Immune Sciences (acquired by Vertex Pharmaceuticals) as well as the Head of Autoimmune Franchise at Annexon Biosciences. Min was trained as a neurologist, received her MD from Suzhou Medical College and Master of Science in Immunology from the University of Calgary.
Seminars
Join this session to hear the thoughts of experts who have successfully moved precision therapies from the oncology world into autoimmune diseases:
- Discussing whether the therapeutic goal should be complete depletion of peripheral B-cells or elimination of tissue resident B-cells that drive local pathology
- Addressing the risks associated at various level of depletion such as elevated BAFF
- Debating whether targeted depletion of specific pathogenic subsets is superior to non-selective deep depletion
- Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
- Harnessing available clinical data to inform target selection and match T-cell engager targets to the correct autoimmune indication
- Exploring the dosing challenges for high-efficacy T-cell engagers and determining whether intermittent high doses or continuous lower doses are optimal to balance efficacy and safety
